Diabetic retinopathy

December 20, 2018

Valproic acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Valproic acid, Epicatechin and Matrine (VAEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 20/December/2018, 11.08 pm

Valproic acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Valproic acid, Epicatechin and Matrine (VAEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 20/December/2018, 11.08 pm https://genomediscovery.org/wp-content/uploads/2018/12/Valproic-acid-attenuates-diabetic-retinopathy-through-induction-of-NRF2.jpg1_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/Valproic-acid-attenuates-diabetic-retinopathy-through-induction-of-NRF2.jpg1_.jpg December 20, 2018 December 20, 2018

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

December 20, 2018

MANF-based therapy for diabetic retinopathy: MANF (Mesencephalic astrocyte derived neurotrophic factor) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down-regulation of its target gene, 20/December/2018, 10.18 pm

MANF-based therapy for diabetic retinopathy: MANF (Mesencephalic astrocyte derived neurotrophic factor) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down-regulation of its target gene, 20/December/2018, 10.18 pm https://genomediscovery.org/wp-content/uploads/2018/12/MANF-attenuates-diabetic-retinopathy-through-induction-of-NRF2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/MANF-attenuates-diabetic-retinopathy-through-induction-of-NRF2.jpg December 20, 2018 December 20, 2018

November 17, 2018

Probiotic-based therapy for diabetic retinopathy: Probiotic Bifidobacterium lactis HY8101 inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down-regulation of its target gene, 17/November/2018, 8.35 am

Probiotic-based therapy for diabetic retinopathy: Probiotic Bifidobacterium lactis HY8101 inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down-regulation of its target gene, 17/November/2018, 8.35 am https://genomediscovery.org/wp-content/uploads/2018/11/Bifidobacterium-lactis-HY8101-inhibits-EPHX2.sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-DHDP-levels1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/11/Bifidobacterium-lactis-HY8101-inhibits-EPHX2.sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-DHDP-levels1.jpg November 17, 2018 November 17, 2018

October 22, 2018

Repurposing the anti-hypertensive drug Diazoxide into a diabetic retinopathy drug: A pharmaceutical mixture encompassing Diazoxide, Epicatechin and Matrine (DEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down-regulation of its target gene, 22/October/2018, 11.34 pm

Repurposing the anti-hypertensive drug Diazoxide into a diabetic retinopathy drug: A pharmaceutical mixture encompassing Diazoxide, Epicatechin and Matrine (DEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down-regulation of its target gene, 22/October/2018, 11.34 pm https://genomediscovery.org/wp-content/uploads/2018/10/Diazoxide-inhibits-EPHX2-expression-decreases-1920-dihydroxydocosapentaenoic-acid-levels.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/10/Diazoxide-inhibits-EPHX2-expression-decreases-1920-dihydroxydocosapentaenoic-acid-levels.jpg October 22, 2018 November 17, 2018

August 19, 2018

Repurposing the anti-angina drug Ranolazine into a diabetes retinopathy drug: A pharmaceutical mixture encompassing Ranolaxine, Epicatechin and Matrine (REM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down-regulation of its target gene, 20/August/2018, 12.05 am

Repurposing the anti-angina drug Ranolazine into a diabetes retinopathy drug: A pharmaceutical mixture encompassing Ranolaxine, Epicatechin and Matrine (REM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down-regulation of its target gene, 20/August/2018, 12.05 am https://genomediscovery.org/wp-content/uploads/2018/08/Ranolazine-Epicatechin-and-Matrine-REM-inhibits-EPHX2-and-attnuates-diabeteic-retinopathy.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/08/Ranolazine-Epicatechin-and-Matrine-REM-inhibits-EPHX2-and-attnuates-diabeteic-retinopathy.jpg August 19, 2018 August 19, 2018

June 29, 2018

Bacillus Calmette Guerin (BCG) vaccine-based therapy for Diabetic retinopathy: BCG vaccine inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 29/June/2018, 11.15 am

Bacillus Calmette Guerin (BCG) vaccine-based therapy for Diabetic retinopathy: BCG vaccine inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 29/June/2018, 11.15 am https://genomediscovery.org/wp-content/uploads/2018/06/BTI-Figures-June-2018-agents-that-attenuate-EPHX2-protein-promote-insulin-sensitivity-and-attenate-diabetic-retinopathy.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/06/BTI-Figures-June-2018-agents-that-attenuate-EPHX2-protein-promote-insulin-sensitivity-and-attenate-diabetic-retinopathy.jpg June 29, 2018 June 29, 2018

Popular Post